简报:评估处于肺癌筛查年龄上限患者的早期肺癌生存模式
该研究基于加拿大阿尔伯塔省2010至2020年诊断的6401例早期(I或II期)肺癌,按年龄、性别、合并症和是否手术分层分析总生存。结果显示各年龄组5年总生存率随年龄增长而下降,合并症少和接受手术者5年总生存率更高,常超过合并症多或未手术的较年轻队列。作者认为肺癌筛查年龄上限应考虑合并症和治愈性治疗的适合性。
要点
- 女性70-74、75-79、80-84岁5年OS分别为54.7%、47.2%、33.7%。
- 男性70-74、75-79、80-84岁5年OS分别为47.7%、38.0%、24.2%。
- 合并症少和接受手术者5年OS更高,常超过合并症多或未手术的较年轻队列。
核心结论
- 肺癌筛查年龄上限应考虑合并症和治愈性治疗的适合性,因其可显著影响早期肺癌诊断和治疗后的生存。
研究设计与样本
- 研究纳入加拿大阿尔伯塔省2010至2020年诊断的所有早期(I或II期)肺癌病例,共6401例,其中I期占71%、II期占29%。
- 男性占43%,女性占57%。
- 采用Kaplan-Meier法估计总生存(OS),OS定义为从肺癌诊断日期至任何原因死亡或删失的时间。
- 按年龄组和性别报告OS及95%置信区间(CI),并按合并症(Charlson合并症指数)和是否接受手术分层。
主要发现
- 女性70至74岁、75至79岁、80至84岁的5年OS分别为54.7%(95% CI:50.6-58.8)、47.2%(95% CI:42.7-51.7)、33.7%(95% CI:28.4-38.9)。
- 男性70至74岁、75至79岁、80至84岁的5年OS分别为47.7%(95% CI:43.1-52.3)、38.0%(95% CI:33.2-42.8)、24.2%(95% CI:19.2-29.3)。
- 在所有年龄组中,合并症较少者和接受手术作为治疗策略一部分者的5年OS更高,通常超过合并症较多或未接受手术治疗的较年轻队列。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Older individuals have an elevated lung cancer risk but may also have substantial comorbidities that preclude curative treatment options and limit the survival benefits of screening. The objective of this study was to assess early stage lung cancer survival patterns among those at the upper age limit for screening and identify older individuals who have the potential to benefit from lung cancer screening. METHODS: We identified all early stage (I or II) lung cancers diagnosed in Alberta, Canada between 2010 and 2020. Overall survival (OS) was based on the time from the date of lung cancer diagnosis to the date of death (from any cause) or censoring. We estimated OS using the Kaplan-Meier method. We present OS with 95% confidence intervals (CIs) for each age group and sex and stratified by presence of comorbidities (Charlson Comorbidity Index) and receipt of surgery. RESULTS: There were 6401 early stage lung cancers (71% stage I, 29% stage II), of which 43% and 57% were among males and females, respectively. For females, the 5-year OS was 54.7% (95% CI: 50.6-58.8), 47.2% (95% CI: 42.7-51.7), and 33.7% (95% CI: 28.4-38.9) for ages 70 to 74 years, 75 to 79 years, and 80 to 84 years, respectively. For males, the 5-year OS was 47.7% (95% CI: 43.1-52.3), 38.0% (95% CI: 33.2-42.8), and 24.2% (95% CI: 19.2-29.3) for ages 70 to 74 years, 75 to 79 years, and 80 to 84 years, respectively. Across all age groups, the 5-year OS was higher for those with fewer comorbidities and for those who received surgery as part of their treatment strategy, usually surpassing that in younger cohorts with more comorbidities or those who did not receive surgical treatment. CONCLUSIONS: Age limits for lung cancer screening should consider comorbidity and fitness for curative treatment because these can significantly influence the survival after diagnosis and treatment of early lung cancer.
引用
- Warkentin MT, Tammemägi MC, Vakil E, et al. Brief Report: Evaluating Early Stage Lung Cancer Survival Patterns in Patients at the Upper Age Limit for Lung Cancer Screening. J Thorac Oncol. 2024. PMID: 39743140. doi:10.1016/j.jtho.2024.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。